We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Ash Board PhD

Director of Editorial

Contact Us

Latest Content From Ash Board PhD

Opinionated Science Episode 17: I Got COVID-19: Here's What Happened
Podcast

This episode is a COVID-19 podcast with a first-hand focus. Podcast host Ruairi Mackenzie discusses his experience with symptomatic COVID-19. And we also look at the data around COVID-19 risk and age and discuss the emerging problems posed by long COVID.

VIEW

Opinionated Science Episode 16: The Metabolome: The Way to Personalized Healthcare?
Podcast

In this episode, the team discuss the metabolome; the billions of tiny molecules that our cells produce every second. Scientific understanding of the metabolome has leapt forward, opening the door to a better understanding of how to treat disease, how to live a healthier lifestyle and even how trauma can be passed down via our metabolites.

VIEW

Opinionated Science Episode 13: Connecting the Brain: “Thought Tetris”, Brain Privacy and Neuralink
Podcast

In this episode, the team discuss efforts to let your brain communicate beyond the limits of your head. Whilst much of this research is still in early stages, scientists have shown how individuals can share thoughts through brain wave-based games of Tetris, and tech entrepreneurs have looked to a future where brains can be directly joined with computers. We look into these technologies’ potential to help paralysis patients and the ethical implications of a network of interconnected brains.

VIEW

Wuhan COVID-19 Vaccine Trials Show Early Positive Results, Moving Forward to Phase 3 Testing
News

The adenovirus type-5-vectored COVID-19 vaccine was shown to be safe and induced significant immune responses in the majority of recipients after a single immunization.

VIEW

Opinionated Science Episode 7: The Vagus Nerve: A Target to Treat Brain and Body?
Podcast

In this episode, we review the evidence surrounding vagus nerve stimulation (VNS), a therapy approved for epilepsy and depression that backers now want to use to treat a host of other conditions, include autoimmune disease and heart failure. How can scientists fill in the gaps in the VNS knowledge base?

VIEW

First-of-its-Kind Cyclic IMS Promises Unlimited Experimental Opportunities
Industry Insight

Ion mobility spectrometry (IMS) coupled to mass spectrometry (MS) has witnessed significant growth over the last two decades. To better understand IMS, the benefits this technology provides, and exactly what Waters' new SELECT SERIES CyclicTM IMS offers, we spoke to Emma Marsden-Edwards.

VIEW

Waters’ Highly Flexible SYNAPT XS Offers Freedom of Analytical Choice
Industry Insight

A highly flexible and high-resolution mass spectrometer, the SYNAPT™ XS technology from Waters has been developed with the analytical needs of R&D labs in mind. Joanne Ballantyne tells us more about the development of SYNAPT™ XS and the features to which it lends its versatility.

VIEW

A Step Towards Democratization in Mass Spectrometry: Agilent Launch Novel "Self-aware" Mass Detector
Industry Insight

How can vendors ensure their technologies are less complex, and therefore available to a wider range of users, without compromising on the quality of data?

VIEW

Bringing Balance to the Lab
Industry Insight

It is an undeniable fact that the success of most experiments in R&D and analytical labs hinges on reliable weighing. It should go without say that dependable lab balances are critical. Often little focus is given to such a vital cog in the machine.

VIEW

How Might Data-centric Software Solutions Impact Analytical Chemistry Labs?
Industry Insight

At the heart of most analytical chemistry analyses are data, the essential unit of measuring and monitoring not only your test subject but the analytical equipment itself. We spoke to Shawn Anderson, Senior Director of Marketing, Software and Informatics Division at Agilent about the move to data-centric software solutions and what the future may hold.

VIEW